Racemetyrosine is under clinical development by Tyme and currently in Phase I for Non-Small Cell Lung Cancer. According to GlobalData, Phase I drugs for Non-Small Cell Lung Cancer have an 80% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Racemetyrosine’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Racemetyrosine overview

Racemetyrosine (SM-88) is under development for the treatment of relapsed or highly refractory diseases including HR positive, HER2 negative breast cancer, metastatic pancreatic cancer, Ewing sarcoma, non-small cell lung cancers, glioblastoma, renal cancer, thyroid cancer, colon cancer, hodgkin’s lymphoma, non-hodgkin’s lymphoma, head and neck cancer and soft-tissue sarcoma. It was also under development for the treatment of ovarian cancer, prostate cancer, breast cancer as a transdermal administration and osteosarcoma. It is a small molecule administered through oral, nasal, and parenteral routes. It acts by targeting tyrosine 3-monooxygenase.

For a complete picture of Racemetyrosine’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 20 May 2024

Premium Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.